Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Shares Outstanding (2017 - 2025)

Gsk has reported Shares Outstanding over the past 9 years, most recently at $5.7 billion for Q4 2025.

  • Quarterly results put Shares Outstanding at $5.7 billion for Q4 2025, up 3.66% from a year ago — trailing twelve months through Dec 2025 was $5.7 billion (up 3.66% YoY), and the annual figure for FY2025 was $5.7 billion, up 3.66%.
  • Shares Outstanding for Q4 2025 was $5.7 billion at Gsk, up from $5.5 billion in the prior quarter.
  • Over the last five years, Shares Outstanding for GLAXF hit a ceiling of $7.3 billion in Q4 2021 and a floor of $5.1 billion in Q4 2022.
  • Median Shares Outstanding over the past 5 years was $5.5 billion (2024), compared with a mean of $5.8 billion.
  • Biggest five-year swings in Shares Outstanding: crashed 30.36% in 2022 and later increased 5.84% in 2023.
  • Gsk's Shares Outstanding stood at $7.3 billion in 2021, then crashed by 30.36% to $5.1 billion in 2022, then rose by 5.84% to $5.4 billion in 2023, then increased by 3.46% to $5.5 billion in 2024, then rose by 3.66% to $5.7 billion in 2025.
  • The last three reported values for Shares Outstanding were $5.7 billion (Q4 2025), $5.5 billion (Q4 2024), and $5.4 billion (Q4 2023) per Business Quant data.